- AZD5305 More Tolerable than 1st-Generation PARP Inhibitors.
- [No author given]
- Cancer Discov. 2022 May 26:OF1. doi: 10.1158/2159-8290.CD-NB2022-0039. Epub ahead of print.
- PMID: 35616497
- PubMed abstract
- Source abstract
- News
Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)
Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)
Original research:
Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.